HRP20140926T1 - Terapeutske formulacije faktora rasta keratinocita - Google Patents
Terapeutske formulacije faktora rasta keratinocita Download PDFInfo
- Publication number
- HRP20140926T1 HRP20140926T1 HRP20140926TT HRP20140926T HRP20140926T1 HR P20140926 T1 HRP20140926 T1 HR P20140926T1 HR P20140926T T HRP20140926T T HR P20140926TT HR P20140926 T HRP20140926 T HR P20140926T HR P20140926 T1 HRP20140926 T1 HR P20140926T1
- Authority
- HR
- Croatia
- Prior art keywords
- kgf
- vol
- composition according
- concentration
- seq
- Prior art date
Links
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 title claims 22
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 title claims 22
- 239000000203 mixture Substances 0.000 title claims 17
- 238000009472 formulation Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 201000004384 Alopecia Diseases 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 229930195725 Mannitol Natural products 0.000 claims 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 4
- 229940068977 polysorbate 20 Drugs 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 2
- 206010063655 Erosive oesophagitis Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 206010017865 Gastritis erosive Diseases 0.000 claims 2
- 206010019663 Hepatic failure Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 208000000203 Hyaline Membrane Disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 claims 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims 2
- 201000010927 Mucositis Diseases 0.000 claims 2
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 206010068168 androgenetic alopecia Diseases 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 210000001198 duodenum Anatomy 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 210000003780 hair follicle Anatomy 0.000 claims 2
- 231100000753 hepatic injury Toxicity 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 231100000835 liver failure Toxicity 0.000 claims 2
- 208000007903 liver failure Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 210000001732 sebaceous gland Anatomy 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 210000000106 sweat gland Anatomy 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (17)
1. Liofilizirana kompozicija faktora rasta keratinocita (KGF) koja sadrži:
• KGF u koncentraciji između 3 mg/mL i 15 mg/mL;
• histidin kao pufer;
• punjač manitol u koncentraciji od 2% do 5% tež./vol.;
• saharozu u koncentraciji od 1% do 3% tež./vol.;
• polisorbat 20 u koncentraciji unutar opsega od 0.004% do 0.1% tež./vol.; i gdje je pH u opsegu od 6.0 do 8.0.
2. Kompozicija prema patentnom zahtjevu 1 naznačena time što je KGF izabran iz grupe koju čine SEQ ID NO: 2, SEQ ID NO: 3.
3. Kompozicija prema patentnom zahtjevu 1 naznačena time što KGF sadrži aminokiselinsku sekvencu od SEQ ID NO: 2.
4. Kompozicija prema patentnom zahtjevu 1 naznačena time što KGF sadrži ΔN23 KGF naveden u SEQ ID NO: 3.
5. Kompozicija prema patentnom zahtjevu 1 naznačena time što manitol je u koncentraciji od 4% tež./vol.
6. Kompozicija prema patentnom zahtjevu 1 naznačena time što saharoza je 2% tež./vol.
7. Kompozicija prema patentnom zahtjevu 1 naznačena time što pH je u opsegu od 6.0 do 7.0.
8. Kompozicija prema patentnom zahtjevu 7 naznačena time što pH je 6.5.
9. Kompozicija prema patentnom zahtjevu 1 naznačena time što koncentracija polisorbata 20 je 0.01% tež./vol.
10. Kompozicija prema patentnom zahtjevu 1 naznačena time što koncentracija KGF je 5 mg/mL.
11. Liofilizirana KGF kompozicija prema patentnom zahtjevu 1 koja sadrži 10 mM histidin, 4% tež./vol. manitol, 2% tež./vol. saharoze i 0.01% (tež./vol.) polisorbata 20, pri čemu je kompozicija na pH od 6.5.
12. Postupak za pripremu liofilizirane KGF kompozicije prema patentnom zahtjevu 1 koji sadrži korake
a) pripreme otopine KGF u koncentraciji između 3 mg/mL i 15 mg/mL; histidina kao pufera; manitola u koncentraciji od 2% do 5% tež./vol.; saharoze u koncentraciji od 1% do 3% tež./vol.; polisorbata 20 u koncentraciji unutar opsega od 0.004% do 0.1% tež./vol., pri čemu je pH u opsegu od 6.0 do 8.0; i
b) liofilizacije navedene otopine KGF da bi se dobila navedena liofilizirana kompozicija KGF.
13. Postupak prema patentnom zahtjevu 12 naznačen time što je KGF izabran iz grupe koju čine SEQ ID NO: 2, SEQ ID NO: 3.
14. Postupak prema patentnom zahtjevu 12 naznačen time što KGF sadrži aminokiselinsku sekvencu od SEQ ID NO: 2.
15. Postupak prema patentnom zahtjevu 12 naznačen time što KGF sadrži ΔN23 KGF naveden u SEQ ID NO: 3.
16. Upotreba liofilizirane kompozicije KGF prema patentnom zahtjevu 1 za pripremu lijeka za liječenje crijevne toksičnosti; mukozitisa; opekotina ili drugih povreda djelomične i potpune debljine; repopulaciju folikula dlake, znojnih žlijezda i lojnih žlijezda; proliferacije adneksalne strukture; epidermolizis buloze; alopecije inducirane kemoterapijom; muške ćelavosti; čireva na želudcu; čireva na duodenumu; erozivnog gastritisa, ezofagitisa, ili ezofagealnog refluksa; inflamatorne bolesti crijeva; bolesti hijalinske membrane; povreda od udisanja dima; emfizema; ciroze jetre, insuficijencije jetre, akutnog virusnog hepatitisa, drugih toksičnih povreda jetre; ili bolesti transplanta protiv domaćina (GVHD), povećanjem KGF-posredovane stimulacije rasta epitelnih stanica.
17. Liofilizirana kompozicija KGF prema patentnom zahtjevu 1, za uporabu u liječenju crijevne toksičnosti; mukozitisa; opekotina ili drugih povreda djelomične i potpune debljine; repopulacije folikula dlake, znojnih žlijezda i lojnih žlijezda; proliferacije adneksalne strukture; epidermolizis buloze; alopecije inducirane kemoterapijom; muške ćelavosti; čireva na želudcu; čireva na duodenumu; erozivnog gastritisa, ezofagitisa, ili ezofagealnog refluksa; inflamatorne bolesti crijeva; bolesti hijalinske membrane; povreda od udisanja dima; emfizema; ciroze jetre, insuficijencije jetre, akutnog virusnog hepatitisa, drugih toksičnih povreda jetre; ili bolesti transplanta protiv domaćina (GVHD), povećanjem KGF-posredovane stimulacije rasta epitelnih stanica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63621004P | 2004-12-15 | 2004-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140926T1 true HRP20140926T1 (hr) | 2014-11-07 |
Family
ID=36337531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140926TT HRP20140926T1 (hr) | 2004-12-15 | 2014-09-26 | Terapeutske formulacije faktora rasta keratinocita |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8304387B2 (hr) |
| EP (1) | EP1827483B1 (hr) |
| JP (1) | JP5201992B2 (hr) |
| KR (1) | KR101283736B1 (hr) |
| CN (1) | CN101084008B (hr) |
| AR (1) | AR052339A1 (hr) |
| AU (1) | AU2005317166B2 (hr) |
| BR (1) | BRPI0519070A2 (hr) |
| CA (1) | CA2589889C (hr) |
| CR (1) | CR9246A (hr) |
| DK (1) | DK1827483T3 (hr) |
| EA (1) | EA013369B1 (hr) |
| ES (1) | ES2504441T3 (hr) |
| HR (1) | HRP20140926T1 (hr) |
| IL (1) | IL183435A (hr) |
| MX (1) | MX2007006822A (hr) |
| MY (1) | MY145638A (hr) |
| NO (1) | NO20073629L (hr) |
| NZ (1) | NZ555503A (hr) |
| PL (1) | PL1827483T3 (hr) |
| PT (1) | PT1827483E (hr) |
| RS (1) | RS53548B1 (hr) |
| SI (1) | SI1827483T1 (hr) |
| TW (1) | TWI351966B (hr) |
| UA (1) | UA88497C2 (hr) |
| WO (1) | WO2006065861A2 (hr) |
| ZA (1) | ZA200706095B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA88497C2 (ru) | 2004-12-15 | 2009-10-26 | Биовитрум Аб (Пабл) | Терапевтические композиции кератиноцитарного фактора роста |
| US20090186805A1 (en) * | 2006-07-06 | 2009-07-23 | Aaron Thomas Tabor | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance |
| KR100784134B1 (ko) * | 2006-10-09 | 2007-12-12 | 주식회사 대웅 | 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물 |
| CN101780269A (zh) * | 2009-01-21 | 2010-07-21 | 北京三有利科技发展有限公司 | 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用 |
| IT1396020B1 (it) * | 2009-10-16 | 2012-11-09 | Fitologica Srl | Composizione topica a base di biopeptidi, e suo utilizzo in campo tricologico. |
| CN102675449B (zh) * | 2011-03-17 | 2016-06-08 | 重庆富进生物医药有限公司 | 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途 |
| CN102379838B (zh) * | 2011-11-02 | 2013-06-12 | 广州舒泰生物技术有限公司 | 一种舒缓静颜化妆品的制备方法及应用 |
| EP2773364A1 (en) * | 2011-11-02 | 2014-09-10 | The University of Chicago | Stable pharmaceutical formulations of growth factor peptides |
| US20150126433A1 (en) * | 2012-04-25 | 2015-05-07 | University Of Cincinnati | Growth factors for the treatment of mycobacterial infection |
| US10588949B2 (en) | 2013-03-15 | 2020-03-17 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
| WO2015148444A1 (en) | 2014-03-24 | 2015-10-01 | Biogen Ma Inc. | Lyophilized factor ix formulations |
| CN108359634A (zh) * | 2018-02-02 | 2018-08-03 | 江阴司特易生物技术有限公司 | 一种饲养细胞蛋白复合物及其应用 |
| CN109402130A (zh) * | 2018-11-23 | 2019-03-01 | 成都中医药大学附属医院 | 一种重组人角质细胞生长因子-1及其制备方法和用途 |
| SG11202113022UA (en) * | 2019-06-24 | 2021-12-30 | Hangzhou Dac Biotech Co Ltd | A formulation of a conjugate of a tubulysin analog to a cell-binding molecule |
| CN110339345B (zh) * | 2019-07-30 | 2022-11-29 | 重庆派金生物科技有限公司 | 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用 |
| EP4183796A1 (en) | 2021-11-19 | 2023-05-24 | Enantis s.r.o. | Thermostable fgf10 polypeptide or fragment thereof use thereof |
| CN119632934A (zh) * | 2025-02-19 | 2025-03-18 | 杭州熙岭生物科技有限公司 | 一种kgf-2组合物的冻干粉及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008771A1 (en) | 1989-01-31 | 1990-08-09 | Rubin Jeffrey S | Dna encoding a growth factor specific for epithelial cells |
| US7026291B1 (en) | 1989-01-31 | 2006-04-11 | The United States Of America As Represented By The Department Of Health And Human Services | Epithelial cell specific growth factor, keratinocyte growth factor (KGF) |
| AU667503B2 (en) * | 1991-12-20 | 1996-03-28 | Novo Nordisk Health Care Ag | A stabilized pharmaceutical formulation comprising growth hormone and histidine |
| EP0706563B1 (en) | 1993-06-29 | 2004-10-06 | Chiron Corporation | A truncated keratinocyte growth factor (kgf) having increased biological activity |
| US7084119B2 (en) | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| EP0785950B1 (en) | 1994-10-13 | 2003-04-16 | Amgen Inc., | Keratinocyte growth factor analogs |
| US6008328A (en) | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
| ES2273338T3 (es) | 1994-10-13 | 2007-05-01 | Amgen Inc. | Metodo para el tratamiento de la diabetes mellitus usando kfg. |
| US6790439B1 (en) * | 1995-06-07 | 2004-09-14 | Zymogenetics, Inc. | Thrombopoietin compositions |
| JPH11510170A (ja) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
| CA2272854C (en) * | 1996-12-06 | 2004-02-10 | Amgen Inc. | Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives |
| US20020012961A1 (en) * | 1999-04-15 | 2002-01-31 | Genentech, Inc. | Fibroblast growth factor- 19 |
| KR20010033484A (ko) * | 1997-12-22 | 2001-04-25 | 휴먼 게놈 사이언시즈, 인크. | 각질세포 성장 인자-2 제제 |
| KR20020010920A (ko) * | 1999-06-02 | 2002-02-06 | 추후제출 | 각질세포 성장 인자-2 제제 |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| UA88497C2 (ru) | 2004-12-15 | 2009-10-26 | Биовитрум Аб (Пабл) | Терапевтические композиции кератиноцитарного фактора роста |
-
2005
- 2005-12-12 UA UAA200707966A patent/UA88497C2/ru unknown
- 2005-12-12 ES ES05853972.7T patent/ES2504441T3/es active Active
- 2005-12-12 BR BRPI0519070-3A patent/BRPI0519070A2/pt not_active IP Right Cessation
- 2005-12-12 CA CA2589889A patent/CA2589889C/en not_active Expired - Fee Related
- 2005-12-12 PL PL05853972T patent/PL1827483T3/pl unknown
- 2005-12-12 MX MX2007006822A patent/MX2007006822A/es active IP Right Grant
- 2005-12-12 PT PT58539727T patent/PT1827483E/pt unknown
- 2005-12-12 JP JP2007546844A patent/JP5201992B2/ja not_active Expired - Fee Related
- 2005-12-12 US US11/302,033 patent/US8304387B2/en active Active
- 2005-12-12 CN CN2005800433149A patent/CN101084008B/zh not_active Expired - Fee Related
- 2005-12-12 RS RSP20140512 patent/RS53548B1/en unknown
- 2005-12-12 KR KR1020077013435A patent/KR101283736B1/ko not_active Expired - Fee Related
- 2005-12-12 EA EA200701293A patent/EA013369B1/ru not_active IP Right Cessation
- 2005-12-12 AU AU2005317166A patent/AU2005317166B2/en not_active Ceased
- 2005-12-12 WO PCT/US2005/045169 patent/WO2006065861A2/en active Application Filing
- 2005-12-12 NZ NZ555503A patent/NZ555503A/en not_active IP Right Cessation
- 2005-12-12 SI SI200531886T patent/SI1827483T1/sl unknown
- 2005-12-12 DK DK05853972.7T patent/DK1827483T3/da active
- 2005-12-12 EP EP05853972.7A patent/EP1827483B1/en active Active
- 2005-12-14 AR ARP050105231A patent/AR052339A1/es unknown
- 2005-12-15 TW TW094144470A patent/TWI351966B/zh not_active IP Right Cessation
- 2005-12-15 MY MYPI20055903A patent/MY145638A/en unknown
-
2007
- 2007-05-27 IL IL183435A patent/IL183435A/en not_active IP Right Cessation
- 2007-07-13 ZA ZA200706095A patent/ZA200706095B/xx unknown
- 2007-07-13 NO NO20073629A patent/NO20073629L/no not_active Application Discontinuation
- 2007-07-13 CR CR9246A patent/CR9246A/es unknown
-
2014
- 2014-09-26 HR HRP20140926TT patent/HRP20140926T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140926T1 (hr) | Terapeutske formulacije faktora rasta keratinocita | |
| JP6309590B2 (ja) | フラビウィルス科ウィルス感染治療用の修飾２’および３’−ヌクレオシドプロドラッグ | |
| JP4923216B2 (ja) | 化合物 | |
| ES2201484T3 (es) | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. | |
| KR102456417B1 (ko) | Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드 | |
| US20150017124A1 (en) | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| CN103842369A (zh) | 用于治疗病毒感染的化合物和药物组合物 | |
| CN1972696A (zh) | 用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯 | |
| ME00556A (en) | Freeze-dried pantoprazole preparation and pantoprazole injection | |
| JP2002516273A (ja) | 治療用ジヌクレオチドおよび誘導体 | |
| UA124966C2 (uk) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N6-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ | |
| JP2008514639A (ja) | フラビウイルス、ペスチウイルス及びヘパシウイルスの感染症を治療するための方法及び組成物 | |
| KR101425228B1 (ko) | 암의 치료를 위한 디옥솔란 유도체 | |
| CN101172992A (zh) | 用于治疗黄病毒感染的修饰的2′和3′－核苷前药 | |
| EP2041161A1 (de) | Chirale mit phosphonsäureester- oder phosphonsäure- substituierte verbindungen | |
| RU2366661C2 (ru) | Пролекарства модифицированных 2'- и 3'-нуклеозидов для лечения инфекций flaviviridae | |
| RU2776918C2 (ru) | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний | |
| WO2022170396A1 (en) | Agents and methods for therapy and prophylaxis | |
| ES2341603B1 (es) | Derivados de nucleosidos para el tratamiento de infecciones por leishmania. | |
| JPH01258698A (ja) | 新しい架橋を伴うａｎｆ誘導体 | |
| JPS61194099A (ja) | アシル化ヘキソース誘導体及び該誘導体を含む医薬製剤 | |
| JPWO2002072131A1 (ja) | 肝疾患治療薬 | |
| HK1142342B (en) | Cyclic, cystein-free protein | |
| BRPI0408526A (pt) | copolìmero ou um sal deste farmacologicamente aceitável, composição farmacêutica, modificador capaz de modificar uma proteìna ou um análogo ou variante desta, complexo, métodos para prolongar o tempo em que uma proteìna ou um análogo ou variante desta são retidos na corrente sangüìnea depois da administração a um paciente, e para o tratamento ou profilaxia de uma doença em um paciente que é suscetìvel a uma proteìna ou um análogo ou variante desta, e, uso do complexo | |
| HK1189234A (en) | Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections |